Contribute Try STAT+ Today

BOSTON — The metronomic rate of failure in Alzheimer’s disease can be crushing to scientists and bankrupting to industry. But when success is in such short supply, every little light through the cracks gets put through a kaleidoscope and parsed for signs of hope.

Such was the case at this year’s Clinical Trials in Alzheimer’s Disease conference, where an onslaught of negative studies got autopsied for lessons that might inform future trials — and signals that once-failed drugs may yet thrive.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.